title: The therapeutic effect of PEI-Mn0.5Zn0.5Fe2O4 nanoparticles/pEgr1-HSV-TK/GCV associated with radiation and magnet-induced heating on hepatoma.
abstract: Comprehensive therapy based on the integration of hyperthermia, radiation, gene therapy and chemotherapy is a promising area of study in cancer treatment. Using PEI-Mn(0.5)Zn(0.5)Fe(2)O(4) nanoparticles (PEI-MZF-NPs) as a gene transfer vector, the authors transfected self-prepared pEgr1-HSV-TK into HepG2 cells and measured the expression of the exogenous gene HSV-TK by RT-PCR. The results showed that HSV-TK was successfully transfected into HepG2 cells and the expression levels of HSV-TK remained stable. Besides, PEI-MZF-NPs were used as magnetic media for thermotherapy to treat hepatoma by magnet-induced heating, combined with radiation-gene therapy. Both in vitro and in vivo results suggest that this combined treatment with gene, radiation and heating has a better therapeutic effect than any of them alone. The apoptotic rate and necrotic rate of the combined treatment group was 51.84% and 15.45%, respectively. In contrast, it was only 20.55% and 6.80% in the radiation-gene group, 7.49% and 3.62% in the radiation-alone group, 15.23% and 7.90% in the heating-alone group, and only 3.52% and 2.16% in the blank control group. The inhibition rate of cell proliferation (88.5%) of the combined treatment group was significantly higher than that of the radiation-gene group (59.5%), radiation-alone group (37.6%) and heating-alone group (60.6%). The tumor volume and mass inhibition rate of the combined treatment group was 94.45% and 93.38%, respectively, significantly higher than 41.28% and 33.58% of the radiation-alone group, 60.76% and 52.18% of the radiation-gene group, 79.91% and 77.40% of the heating-alone group. It is therefore concluded that this combined application of heating, radiation and gene therapy has a good synergistic and complementary effect and PEI-MZF-NPs can act as a novel non-viral gene vector and magnetic induction medium, which offers a viable approach for the treatment of cancer.
authors.affiliation: Medical School of Southeast University, No. 87 Dingjiaqiao Road, Nanjing, 210009, Jiangsu Province, China.
authors.forename: Mei
authors.initials: M
authors.lastname: Lin
authors.forename: Junxing
authors.initials: J
authors.lastname: Huang
authors.forename: Jia
authors.initials: J
authors.lastname: Zhang
authors.forename: Li
authors.initials: L
authors.lastname: Wang
authors.forename: Wei
authors.initials: W
authors.lastname: Xiao
authors.forename: Hong
authors.initials: H
authors.lastname: Yu
authors.forename: Yuntao
authors.initials: Y
authors.lastname: Li
authors.forename: Hongbo
authors.initials: H
authors.lastname: Li
authors.forename: Chenyan
authors.initials: C
authors.lastname: Yuan
authors.forename: Xinxin
authors.initials: X
authors.lastname: Hou
authors.forename: Hao
authors.initials: H
authors.lastname: Zhang
authors.forename: Dongsheng
authors.initials: D
authors.lastname: Zhang
mesh_terms: D003131:Combined Modality Therapy / Q000379:methods; D015316:Genetic Therapy / Q000379:methods*; D056945:Hep G2 Cells; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods*; D055909:Magnetic Field Therapy / Q000379:methods*; D053769:Nanocapsules / Q000008:administration & dosage* / Q000737:chemistry; D009374:Neoplasms, Experimental / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D011878:Radiotherapy / Q000379:methods*; D013937:Thymidine Kinase / Q000235:genetics / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D053769:Nanocapsules; D013937:Thymidine Kinase